Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies for the treatment of major depressive disorder (MDD). The MDD treatment armamentarium is becoming increasingly genericized, a trend that has improved patient access to antidepressants, as well as eased restrictions on off-label adjunctive use of atypical antipsychotics. At the same time, the expanding presence of generic drugs has given payers more leverage to control drug treatment costs in MDD. Understanding the current and expected influence of clinical metrics and value-for-dollar on market access and medical practice is key for developers of new therapies for MDD.
- In this mature and highly generic treatment landscape, what actions can marketers of MDD therapies taketo gain market access and thus ensure uptake?
- How do payer policies affect the prescribing of branded oral atypical antipsychotics (e.g., Lundbeck/Otsuka Pharmaceutical’s Rexulti, Allergan’s Vraylar) and antidepressants (e.g., Lundbeck/Takeda’s Trintellix, Allergan’s Viibryd) in this genericized market?
- To which of their MDD patients do physicians anticipate prescribing the emerging therapies esketamine (Janssen), gepirone ER (Fabre-Kramer), and rapastinel (Allergan)? How do payers expect to reimburse these therapies?
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.
Markets covered: United States
Primary research: Survey of 50 U.S. primary care physicians, 50 U.S. psychiatrists, and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs) fielded in January 2019.
Key companies: Allergan, Eli Lilly, Fabre-Kramer Pharmaceuticals, Janssen, Lundbeck, Otsuka, Sunovion, Takeda,
Key drugs: Duloxetine (Cymbalta, generics), Latuda, Rexulti, Trintellix, Viibryd, Vraylar, esketamine, gepirone ER, rapastinel
- Reimbursement and contracting
- Access and prescribing
- Special topics
- Opportunities and challenges for emerging therapies
- Unipolar Depression - Access & Reimbursement - Detailed, Expanded Analysis (US) Major Depressive Disorder
- Access & Reimbursement Major Depressive Disorder US June 2019
Lisa Cloonan is a business insights analyst on the CNS/Ophthalmology Disorders team at DRG, part of Clarivate. In this role, she analyzes the commercial opportunities for pharmacological therapies in the psychiatry space. Prior to joining DRG, Ms. Cloonan spent six years researching clinical stroke at Massachusetts General Hospital. While there, she developed expertise in neuroimaging analysis, as well as authored and coauthored articles on the influence of white matter hyperintensity burden on stroke risk and recovery. She holds a bachelor of arts degree from Connecticut College, where her course work focused on behavioral neuroscience.
Andrea Witt, Ph.D.
Andrea S. Witt, Ph.D., is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Clarivate, where she oversees a team of Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.
Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.
Audreza Das, P.G. Dip.
Audreza Das, P.G. Dip., B.E., is a senior analyst on the CNS/Ophthalmology Disorders team at DRG, part of Clarivate. She has authored content on neuropathic pain, age-related macular degeneration, attention-deficit/hyperactivity disorder, unipolar depression, bipolar disorder, treatment-related depression, postherpetic neuralgia, painful diabetic neuropathy, and migraine. Ms. Das obtained her P.G. Dip. in cancer immunology and biotechnology from the University of Nottingham and a B.E. in biotechnology from the Birla Institute of Technology.